Sector Expert: David Lowe

NeuroAssets

Image: David Lowe

Dr. David A. Lowe is president and CEO of NeuroAssets Sarl, a Swiss-based neuroscience-focused consulting firm providing advisory services to pharmaceutical, venture capital and biotechnology companies throughout the world. Lowe previously served as the chief scientific officer of PsychoGenics Inc., and before that as director and chief scientific officer of Memory Pharmaceuticals Corp., a biotechnology company pursuing innovative treatments for Alzheimer's disease and schizophrenia. Prior to Memory Pharmaceuticals, Lowe served as the executive vice president and chief scientific officer at Fidelity Biosciences Group, Fidelity Investments, in Boston, an investment firm focused on the healthcare industry. He also served as president, CEO and director of EnVivo Pharmaceuticals, a Fidelity-funded pharmaceutical company pursuing new treatments for Alzheimer's disease. Lowe has also served as vice president and therapeutic area head, central nervous system (CNS), at Roche Pharmaceuticals, vice president and global therapeutic area head (CNS), at Bayer AG, and head of CNS biology, as well as deputy head of CNS research at Sandoz (now Novartis). He received his PhD in neurobiology from the University of Leeds, UK.



Recent Quotes

"We believe AMBS' MANF molecule is one of the jewels in the field."

The Life Sciences Report Interview with David Lowe (3/26/14)
more >



Due to permission requirements, not all quotes are shown.